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Abstract
Objective—To identify specific ECG and clinical predictors that separate atherosclerotic sudden
cardiac death (SCD) from incident coronary heart disease (CHD) (non-fatal events and non-
sudden death) in the combined cohorts of the Atherosclerosis Risk in Communities study and the
Cardiovascular Health Study.
Methods—This analysis included 18 497 participants (58% females, 24% black individuals,
mean age 58 years) who were initially free of clinical CHD. A competing risk analysis was
conducted to examine the prognostic significance of baseline clinical characteristics and an
extensive electronic database of ECG measurements for prediction of 229 cases of SCD as a first
event versus 2297 incident CHD cases (2122 non-fatal events and 175 non-sudden death) that
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occurred during a median follow-up time of 13 years in the Cardiovascular Health Study and 14
years in the Atherosclerosis Risk in Communities study.
Results—After adjusting for common CHD risk factors, a number of clinical characteristics and
ECG measurements were independently predictive of SCD and CHD. However, the risk of SCD
versus incident CHD was significantly different for race/ethnicity, hypertension, body mass index
(BMI), heart rate, QTc, abnormally inverted T wave in any ECG lead group and level of ST
elevation in V2. Black race/ethnicity (compared to non-black) was predictive of high SCD risk but
less risk of incident CHD (p value for differences in the risk (HR) for SCD versus CHD <0.0001).
Hypertension, increased heart rate, prolongation of QTc and abnormally inverted T wave were
stronger predictors of high SCD risk compared to CHD (p value=0.0460, 0.0398, 0.0158 and
0.0265, respectively). BMI was not predictive of incident CHD but was predictive of high SCD
risk in a quadratic fashion (p value=0.0220). On the other hand, elevated ST height as measured at
the J point and that measured at 60 ms after the J point in V2 were not predictive of SCD but were
predictive of high incident CHD risk (p value=0.0251 and 0.0155, respectively).
Conclusions—SCD and CHD have many risk factors in common. Hypertension, race/ethnicity,
BMI, heart rate, QTc, abnormally inverted T wave in any ECG lead group and level of ST
elevation in V2 have the potential to separate between the risks of SCD and CHD. These results
need to be validated in another cohort.
INTRODUCTION
Sudden cardiac death (SCD) is a major health problem that affects 236 000–325 000 people
in the USA and 350 000–700 000 people in Europe each year.1, 2 Most of these SCD cases
occur outside the hospital with few or no early warning signs.3 Therefore, it is important to
identify those at risk of SCD if preventive measures are to be implemented.
Atherosclerotic coronary heart disease (CHD) is considered the main cause of SCD.4 Nearly
half of all CHD deaths are sudden, and approximately 15% of these deaths are the first
clinical manifestation of disease.5 SCD could also be caused by non-atherosclerotic CHD
and non-CHD causes.6–10 However, these SCD causes are much less common compared to
atherosclerotic CHD causes.
A number of studies have attempted to predict SCD in patients with acute myocardial
infarction (MI) and in other high-risk patient-based populations.11–13 Thus, a number of
ECG and clinical predictors of SCD have already been identified. Nevertheless,
atherosclerotic SCD shares many of the same risk factors of CHD, whether non-fatal or non-
sudden fatal. This creates a challenge in identifying those at risk of SCD while considering
the competing risk of future CHD, especially in the general population. In this analysis from
the combined cohorts of the Atherosclerosis Risk in Communities (ARIC) study and the
Cardiovascular Health Study (CHS), we conducted a competing risk analysis aiming to




The ARIC study is a population-based cohort study designed to investigate the natural
history and aetiology of atherosclerotic and cardiovascular disease events in four US
communities in Maryland, Minnesota, Mississippi and North Carolina. The design,
objectives and recruitment of study participants are described in detail elsewhere.14 Briefly,
at baseline (1987–1989), the cohort was composed of 15 792 men and women 45–64 years
of age who were selected by list of area probability sampling. Eligible participants were
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interviewed at home and invited to a baseline clinical examination where various
cardiovascular risk factors and conditions were measured. Three triennial study visits
occurred subsequently, with the last visit from 1996 to 1998. Additionally, participants or
their proxies were contacted annually by telephone to ascertain hospitalisations and death.
The CHS is an observational cohort study of risk factors for CHD and stroke in older people.
The design, objectives and recruitment of study participants are described in detail
elsewhere.15 Briefly, between 1989 and 1990, four field centres recruited a total of 5201
people 65 years or older from Medicare eligibility lists in four communities in the USA
(North Carolina, California, Maryland, Pennsylvania). To enhance minority representation,
during 1992–1993, 687 African–American participants were recruited in three of the four
field centres. Participants had annual examinations through 1999.
The CHS and ARIC study protocols were approved by the institutional review board of each
participating centre, and informed consent was obtained from each study participant.
There were 21 671 participants in the original combined cohorts with comparable data. After
excluding 629 participants with poor-quality ECG recordings, 1815 with prevalent CHD at
baseline, 10 participants with missing medical records and 57 cases of SCD classified as
‘possible’ and not definite, the data of 19 160 participants remained. We then excluded 663
participants with major conduction defects defined as QRS duration ≥120 ms (eg, complete
left bundle branch block) to allow for an appropriate examination of the ECG variables that
are better interpreted/measured in the absence of major conduction defects (eg, level of ST
elevation, QTc, spatial QRST angle, spatial QRS axis, T axis and ECG-left ventricular
hypertrophy/mass).
ECG variables
Identical electrocardiographs (MAC PC, Marquette Electronics, currently GE Healthcare,
Milwaukee, Wisconsin, USA) were used in all clinic centres for ARIC and CHS, and
standard 12-lead ECGs were recorded in all participants by strictly standardised procedures.
A 10-second segment of simultaneous ECG leads was sampled at a rate of 250 samples per
second. The electronic ECGs stored in the ECG machines were transmitted regularly over
analogue phone lines to a central ECG core laboratory for reading. The ECGs were initially
processed with the Dalhousie ECG program and then were later processed with the 2001
version of the GE Marquette 12-SL program (GE Healthcare). The Marquette measurement
matrix contained several ECG measures of different parts of the ECG waveform. In this
analysis, we included the ECG variables that have the potential to be predictive of SCD and/
or CHD. This included level of ST height as measured at the J point (STJ) and at 60 ms after
the J point (ST60), the amplitude and duration of P, P′, R, R′, Q, S and S′ waves, the R
intrinsicoid deflection, and the amplitude, duration and area of T and T′ waves in each of
the 12 ECG leads. Also included were total QRS duration, axis and area, QT duration (and
QTc by Bazett), PR duration, P wave axis, T wave axis and two time domain short-term
heart rate variability indices: standard deviation of normal RR intervals (SDNN) and root
mean square of successive differences between RR intervals (RMSSD). In addition, the
following indices were created: the frontal plane and spatial QRST angle, spatial T wave and
QRS axis16 and left ventricular mass using a multivariate ECG model.17 In addition to these
continuous ECG variables, a number of categorical variables were derived as well.
Minnesota ECG classification was used to define significant ST depression (Minnesota
Code 4), significant ST elevation (Minnesota Code 9.2) and T wave abnormalities
(Minnesota Code 5).18 Left ventricular hypertrophy was defined by the Cornell voltage
index (RaVL+SV3 ≥2200 μV for women, ≥2600 μV for men).19
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Ascertainment of SCD and CHD events
The ARIC study and CHS have detailed information on cardiovascular disease deaths
including fatal and non-fatal CHD. CHD events included clinical MI, silent MI (made from
the study scheduled ECGs), CHD and coronary artery revascularisation. To standardise the
case definition of SCD in this analysis of the combined cohorts, all cases of fatal CHD that
occurred by July 31, 2002, in CHS (13 years of median follow-up) and December 31, 2002,
in ARIC (14 years of median follow-up) were reviewed and adjudicated by a committee of
physicians. Definite SCD was defined as a sudden pulseless condition of cardiac origin in a
previously stable individual. Possible SCD was defined as death occurring <24 h from a
stable condition for unwitnessed events without other evidence indicating instantaneous
death. Only definite sudden death cases were used in this analysis.
Statistical methods
Cox proportional hazards regression models were used to determine which demographic and
clinical characteristics were associated with the risk of definite SCD and incident CHD
events (excluding definite or possible SCD) and to assess the effects of ECG variables on
these risks after adjustment for the demographic and clinical characteristics and study cohort
(ARIC and CHS). Age was used as the timescale, and birth cohort (<1920, 1920–1929,
1930–1939 and 1940+) was used as a stratification factor in all analyses.20 For each
outcome, a backward stepwise algorithm determined the demographic and clinical
characteristics significantly associated with that outcome. From those, a set of covariates
(shown in table 1) that were associated with either SCD or CHD was selected. A
proportional hazards competing risk analysis21 was then done to determine if the ECG
predictors for the risk of incident CHD differed from those for the risk of definite SCD. Two
additional strata were specified, one for each event type (CHD vs SCD), with all participants
appearing in each stratum. The clinical and demographic characteristics that were
significantly associated with the risk of either CHD or SCD were included in the models.
The ECG variables were then included one at a time in the multivariable models which
included the clinical and demographic covariates. The interaction between each ECG
variables and event type was assessed to determine if the effect of the ECG variable differed
by outcome, adjusting for common covariates. Whenever possible, ECG variables were
included in the models as continuous measurements, and HRs were calculated for 1 SD
increase. All analyses were performed with the SAS system for Windows, V.9.1. (SAS
Institute, Inc.).
RESULTS
After exclusions, 18 497 participants (14 322 from ARIC and 4175 from CHS) were
included in this analysis. The age of the combined cohort ranged from 44 to 95 years
(median 57 years), with 58% females and 24% black individuals. Demographics and clinical
characteristics of the combined cohort that were predictive of the outcomes in the
preliminary analysis and were used later in the competing risk analysis are shown in table 1.
Additional characteristics assessed in the preliminary analyses but not included in the
competing risk analyses are included in the footnote to table 1.
Most participants (N=13 471; 72.8%) had no event during the follow-up period and were
censored in the analysis at their date of last contact. Non-CHD deaths occurred in 2500
(13.5%) participants and were censored at their date of death. As their first event, 229
(1.2%) participants experienced a definite SCD compared to 2297 participants who
experienced a CHD event (2122 (11.5%) non-fatal CHD events and 175 (0.9%) non-sudden
CHD deaths).
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Table 2 shows the results of the multivariable competing risk analysis for the risk of SCD
and incident CHD associated with different demographic and clinical variables. The p values
in the table assess the difference in the HRs for SCD versus incident CHD. As shown,
among the list of CHD risk factors listed in the table, only race/ethnicity, body mass index
(BMI) and hypertension discriminated between the risk of SCD and incident CHD. Black
race/ethnicity (compared to non-black race) was predictive of high SCD risk (HR (95% CI):
1.81 (1.31 to 2.49)) but less risk of incident CHD (0.76 (0.67 to 0.86)); p value for
differences in the HRs <0.0001. Hypertension was a stronger predictor of high SCD risk
compared to CHD (2.17 (1.60 to 2.93) and 1.57 (1.43 to 1.72)); p value for differences in the
HRs=0.0460. BMI was not significantly predictive of incident CHD but was predictive of
high SCD risk in a quadratic fashion; p value for differences in the HRs=0.0220. Figure 1
shows the log(HR) for BMI values ranging from 20 to 50 kg/m2 relative to a BMI of 20 kg/
m2. As shown, the risk of SCD decreases as BMI increases from 20 to 29 and then begins to
increase. On the other hand, the risk of CHD is not greatly related to BMI but decreases
slightly as BMI increases.
Among the large number of ECG variables we used in this analysis, only heart rate; QTc;
abnormally inverted T wave in any ECG lead group and STJ amplitude in leads V2, V3, II,
and aVF, and ST60 in V2 were associated with HRs for SCD that are significantly different
from those for incident CHD, as follows (table 3): Increased heart rate, prolongation of QTc
and presence of abnormally inverted T wave in any ECG lead group were stronger
predictors of high SCD compared to incident CHD (p value for differences in HRs=0.0398
for heart rate, 0.0158 for QTc and 0.0265 for T wave). The ability of the abnormally
inverted Twave in any ECG lead group to discriminate between SCD and CHD was not
driven by a specific ECG lead group (results not shown). Elevated STJ amplitude in leads II,
aVF and V3 was predictive of less SCD risk but was not significantly predictive of incident
CHD. On the other hand, STJ and ST60 in V2 were predictive of high incident CHD risk but
were not significantly predictive of SCD.
Presence of significant ST depression by Minnesota Code in any of the lead groups was
predictive of SCD and incident CHD, but the difference in the HRs did not reach statistical
significance (p=0.532). Similar results were obtained when ST depression was examined in
each of the ECG lead groups separately (results not shown).
Including participants with prevalent CHD at baseline in the cohort showed that the greatest
risk of SCD was a prior CHD event. The risk of SCD was approximately four times higher
for those with prevalent CHD compared to those with no evidence of CHD (95% CI: 3.18 to
5.10), adjusted for age, race/ethnicity and sex. Similarly, including participants with major
conduction defects showed that QRS duration ≥120 ms is significantly predictive of SCD
(1.80 (1.13 to 2.87)) and incident CHD (1.22 (1.02 to 1.46)) but could not distinguish
between the two outcomes (p values for differences in the HRs=0.1230). The results of the
non-ECG variables in table 2 were similar regardless of including or excluding those
participants with major conduction defects.
DISCUSSION
We identified a number of specific predictors separating the risk of SCD from incident CHD
in a cohort of men and women initially free of CHD who were enrolled in two of the largest
community-based studies in the USA: ARIC and CHS. These predictors included race/
ethnicity, hypertension, BMI, heart rate, QTc, abnormally inverted T wave in any ECG lead
group and level of ST elevation (STJ and ST60) in V2. Elevated STJ amplitude in leads V3,
II and aVF was ‘protective’ from SCD but was not associated with incident CHD and,
hence, can be used as a ‘favourable’ marker for less risk of SCD. As expected and given that
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the SCD cases in our study are mostly atherosclerotic, we also showed that many
demographic, clinical and ECG predictors/risk factors are shared between SCD and incident
CHD and, subsequently, could not separate between these two outcomes.
The previously reported association between high resting heart rate and marker of
ventricular arrhythmogenesis independently from myocardial ischaemia22 as well as being
predictive of SCD in post-MI patients and in the general population23–25 may explain why
heart rate was more predictive of SCD in our study. Similarly, prolonged QTc has been
frequently linked to SCD,26 and minor T wave abnormalities have been linked to fatal CHD
but not non-fatal MI, suggesting that T wave abnormalities are harbingers of arrhythmic
sudden death.27 On the other hand, there is no clear explanation why race/ethnicity,
hypertension and BMI were more predictive of SCD than incident CHD. Genetic
predisposition (for race/ethnicity) or indirect effect on the electrophysiology of the heart
(hypertension and BMI) may be part of the explanation—a hypothesis that requires further
investigation.
ST segment elevation has been reported in many conditions and disease states including
acute coronary syndrome, acute pericarditis, early repolarization and Brugada syndrome.
The latter two conditions have been looked at as two extreme examples of conditions
associated with non-atherosclerotic ST elevation. Early repolarization has always been
considered benign, while Brugada syndrome has been associated with sudden death.
Nevertheless, recent reports showed that early repolarization (albeit with an idiosyncratic
definition of early repolarization) could also be associated with sudden death.28 In our study,
ST elevation (STJ and ST60) was mostly protective from SCD. This accords with what is
always believed as a benign nature of early repolarization, in which ST elevation is a key
feature. Differences in the outcomes associated with ST elevation (or early repolarization)
could be explained by differences in the pathophysiological basis of SCD (non-
atherosclerotic vs. atherosclerotic as in our study) or differences in the populations studied
(patient-based vs community-based).
Although presence of STelevation (STJ or ST60) was generally protective from SCD, it was
predictive of high incident CHD risk. This may explain the recently reported increased
cardiovascular and all-cause mortality associated with early repolarization as defined mainly
on the basis of STelevation.29, 30 The mechanism by which ST elevation could be predictive
of high CHD risk is unclear.
Our results should be interpreted in the context of some limitations. We have conducted
many statistical tests without adjusting for multiple comparisons. Thus, some of the positive
results could be due to chance. However, since this analysis is the first attempt to get a
general idea on what could be potentially SCD-specific predictors, adjusting for multiple
comparisons and using a more stringent p value may lead to missing some potentially
important predictors. This is the same reason for using most of the predictor variables in our
analysis as continuous variables in the statistical models (ie, reporting HRs per 1 SD
increase) rather than using arbitrary cut points that can miss important associations which
may exist with other cut points. For example, using ST elevation, whether in any lead group
or separately, as a categorical variable (defined by Minnesota Code) was not predictive of
either SCD or CHD (results not shown), but using ST elevation (STJ and ST60) as a
continuous variable highlighted the potential importance of ST elevation in V2. Noteworthy,
STJ and ST60 in the same lead or in different leads in the same lead group are correlated to
some degree, and subsequently, the tests may not be fully independent. However, we
preferred to test STJ and ST60 in individual leads because different ion channels may be
active at these times or clearly manifested in some leads compared to others. Validation of
the SCD distinguishing predictors which we identified and searching for the optimal cut
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points for these predictors are needed. Another limitation of our study is that we depended
solely on resting standard 12-lead ECG without utilisation of other recent prognostically
important ECG predictors of SCD such as heart rate turbulence, T wave alternans, late
potentials detected by signal-averaged ECG, etc. Nevertheless, lack of widespread
availability of these new ECG predictors would be an obstacle to make practical use of them
even if they proved useful in distinguishing between SCD from CHD.
The strengths of this study are the very large size of the cohort studied and that our
classification of SCD is much more precise and rigorous than that of other investigations.
Also, most of the previous studies on predictors of SCD have ignored the competitive risk of
CHD, which does not provide meaningful risk stratification of patients if definitive
preventive strategies are to be implemented.
In conclusion, SCD and incident CHD have many risk factors in common. However, we
identified specific predictors that have the potential to separate between the risks of SCD
and CHD. These predictors include race/ethnicity, hypertension, BMI, heart rate, QTc,
abnormally inverted T wave in any ECG lead group and level of ST elevation in V2. These
results need to be validated in another cohort.
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Body mass index and risk of SCD and incident CHD. SCD, sudden cardiac death; CHD,
coronary heart disease.
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Table 1
Characteristics of the combined ARIC and CHS cohorts
Characteristic* N Mean±SD or N (%)
Total 18497 18497 (100)
Study 18497
 ARIC 14322 (77)
 CHS 4175 (23)
Age 18497 58.1±9.6
Sex 18497
 Female 10764 (58)
 Male 7733 (42)
Race/ethnicity 18497
 Black 4491 (24)
 Non-black 14006 (76)
Body mass index (kg/m2) 18470 27.4±5.3
Smoking status 18471
 Never 7776 (42)
 Former 6108 (33)
 Current 4587 (25)
Diabetes 18336 2159 (12)
Hypertension 18433 7145 (39)
LDL-cholesterol (mg/dl) 17950 135.5±37.9
HDL-cholesterol (mg/dl) 18208 53.0±16.7
Triglycerides (mg/dl) 18008 125.5±62.9
White blood cell count (×103m/μl) 18080 6.01.7
*
Clinical variables not included because they were not predictive of CHD or SCD include education, family income, family history of
cardiovascular disease, alcohol, asthma, cancer, intermittent claudication, physical activity, forced expiratory volume in 1 s, haematocrit value,
haemoglobin, total calories, ankle brachial index, fasting glucose, insulin, creatinine, fibrinogen and uric acid.
ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
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Table 2
Multivariable competing risk analysis for the risk of SCD and incident CHD associated with different
demographic and clinical variables
Characteristic Definite SCD HR (95% CI)* Incident CHD HR (95% CI)* p Value†
ARIC study (vs CHS) 1.09 (0.62 to 1.89) 0.84 (0.70 to 1.00) 0.3889
Age (per decade)‡ 2.61 (1.71 to 3.97) 1.75 (1.53 to 2.01) 0.0788
Male sex (vs female) 2.42 (1.77 to 3.30) 2.03 (1.84 to 2.24) 0.2930
Black race/ethnicity (vs non-black) 1.81 (1.31 to 2.49) 0.76 (0.67 to 0.86) <0.0001
BMI 0.0220
 BMI (kg/m2) 0.49 (0.23 to 1.03) 1.14 (0.79 to 1.63)
 BMI2 (kg/m2) 1.07 (1.01 to 1.13) 0.99 (0.96 to 1.02)
Smoking status (vs current) 0.7477
 Never 0.59 (0.40 to 0.86) 0.69 (0.61 to 0.78)
 Former 0.70 (0.48 to 1.01) 0.76 (0.68 to 0.85)
Diabetes 2.54 (1.84 to 3.50) 2.08 (1.86 to 2.32) 0.2470
Hypertension 2.17 (1.60 to 2.93) 1.57 (1.43 to 1.72) 0.0460
LDL-cholesterol (mg/dl) 1.12 (0.98 to 1.29) 1.27 (1.22 to 1.33) 0.0869
HDL-cholesterol (mg/dl) 0.92 (0.76 to 1.11) 0.80 (0.75 to 0.86) 0.1880
Triglycerides (mg/dl) 0.99 (0.85 to 1.15) 1.06 (1.02 to 1.11) 0.3517
White blood cell count (×103/μl) 1.27 (1.11 to 1.46) 1.15 (1.11 to 1.21) 0.1759
*
Unless described otherwise, HRs for continuous variables are per 1 SD increase and for the abnormal value for the categorical variables adjusted
for the rest of the variables in the table.
†
Assessing equivalence of HRs for the two end points.
‡
For age, timescale is time since study entry; for all other variables, timescale is age.
BMI, body mass index; CHD, coronary heart disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SCD, sudden cardiac death.
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Table 3
Multivariable competing risk analysis for the risk of SCD and incident CHD associated with different ECG
variables
ECG variable* Definite SCD HR (95% CI)† Incident CHD HR (95% CI)† p Value‡
ECG-LVH 1.74 (1.03 to 2.93) 1.59 (1.30 to 1.94) 0.7522
ECG-LV mass 1.31 (1.06 to 1.61) 1.14 (1.06 to 1.23) 0.2116
Spatial QRST angle 1.30 (1.15 to 1.47) 1.19 (1.14 to 1.24) 0.1835
Spatial T axis 1.14 (1.03 to 1.27) 1.10 (1.06 to 1.15) 0.5540
Frontal QRST angle 1.17 (1.06 to 1.28) 1.13 (1.09 to 1.17) 0.4737
Heart rate 1.21 (1.07 to 1.37) 1.05 (1.01 to 1.10) 0.0398
QTc duration (ms) 1.19 (1.08 to 1.31) 1.05 (1.01 to 1.09) 0.0158
T wave inversion§ 2.03 (1.49 to 2.75) 1.41 (1.27 to 1.56) 0.0265
ST depression§ 2.44 (1.69 to 3.51) 1.66 (1.45 to 1.91) 0.0532
STJ in I (μv) 0.84 (0.74 to 0.95) 0.91 (0.87 to 0.95) 0.2310
STJ in II (μv) 0.78 (0.69 to 0.89) 0.96 (0.92 to 1.00) 0.0029
STJ in aVF (μv) 0.83 (0.73 to 0.94) 1.00 (0.96 to 1.04) 0.0068
STJ in aVL (μv) 0.98 (0.86 to 1.12) 0.93 (0.89 to 0.97) 0.4318
ST60 in I (μv) 0.77 (0.68 to 0.87) 0.86 (0.82 to 0.90) 0.0971
ST60 in II (μv) 0.83 (0.73 to 0.94) 0.92 (0.88 to 0.96) 0.1334
ST60 in III (μv) 1.05 (0.92 to 1.19) 1.05 (1.01 to 1.10) 0.9766
ST60 in aVL (μv) 0.83 (0.73 to 0.94) 0.88 (0.85 to 0.92) 0.3241
STJ in V1 (μv) 1.07 (0.95 to 1.21) 1.10 (1.05 to 1.15) 0.6951
STJ in V2 (μv) 0.93 (0.81 to 1.07) 1.10 (1.05 to 1.15) 0.0251
STJ in V3 (μv) 0.86 (0.75 to 0.99) 1.04 (1.00 to 1.09) 0.0105
STJ in V4 (μv) 0.85 (0.75 to 0.96) 0.96 (0.92 to 1.00) 0.0774
STJ in V5 (μv) 0.83 (0.74 to 0.93) 0.93 (0.89 to 0.97) 0.0841
STJ in V6 (μv) 0.82 (0.73 to 0.92) 0.91 (0.87 to 0.95) 0.1542
ST60 in V1 (μv) 1.10 (0.98 to 1.25) 1.14 (1.09 to 1.18) 0.6588
ST60 in V2 (μv) 0.91 (0.78 to 1.05) 1.10 (1.05 to 1.15) 0.0155
ST60 in V4 (μv) 0.84 (0.73 to 0.97) 0.93 (0.89 to 0.98) 0.1722
ST60 in V5 (μv) 0.81 (0.72 to 0.92) 0.88 (0.84 to 0.92) 0.2114
ST60 in V6 (μv) 0.82 (0.72 to 0.92) 0.87 (0.84 to 0.91) 0.2668
*
Other ECG variables tested for predictive value but not found significant for either outcomes in the preliminary analysis or the competing analysis
were excluded from the table. This included QRS duration, spatial QRS axis, ST60 in V3, STJ in III, ST60 in aVF, the amplitude and duration of P,
P′, R, R′, Q, S and S′ waves, the R intrinsicoid deflection, T and T′ amplitude, duration and area in each of the 12 ECG leads as well as total
QRS duration, axis and area, QT (and QTc by Bazett) duration, PR duration, P wave axis, T wave axis, and time domain heart rate variability
indices of SDNN and RMSSD and ST elevation by Minnesota Code.
†
Unless described otherwise, HRs for continuous variables are per 1 SD increase and for the abnormal value for categorical variables adjusted for
the variables in table 2.
‡
Assessing equivalence of HRs for the two end points.
§
Abnormally inverted T wave and significant ST depression were defined by Minnesota Code as abnormality in any of the ECG lead groups:
anterior, lateral or inferior.
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SCD, sudden cardiac death; CHD, coronary heart disease; STJ, ST height as measured at the J point; ST60, ST height as measured at 60 ms after
the J point.
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